30 results about "Skov3 cell" patented technology

The invention relates to a multidrug resistant cell strain for oophoroma, which is characterized in that a human oophoroma SKOV3 cell strain is selected as a parental cell; the action concentration of chemotherapeutics of etoposide (VP16) is gradually increased from 0.1 mu g/ml to 3 mu g/ml; and drug resistant SKOV3/VP16 cell strain is established. The SKOV3/VP16 cell can stably grow, transfer and reanimate in 3 mu g/ml VP16, makes the VP16 generate drug resistant index (RI) of 21.548, and performs intersect drug on MTX, DOX, DDP, VCR, 5-Fu and MMC except the VP16. The invention aims to provide a drug resistant tumor cell model for relative study on the tumor.

The invention discloses a platinum complex for inhibiting cell SKOV3 and a synthesis method of the platinum complex, belongs to the technical field of medicines, and aims to provide a cell SKOV3 inhibiting platinum complex synthesized from rutaecarpine as structural basis and DMSO as an auxiliary ligand. The invention further provides a synthesis method of the platinum complex. The structural formula of the platinum complex is as shown in the description. The platinum complex can be used for preparing anti-tumor drugs.

The invention discloses application of a carbon quantum dots/cuprous oxide (CQDs/Cu2O) compound to preparation of cancer treating medicines. Through in-vitro cell experiments, the anticancer activityof the CQDs/Cu2O is explored; after the CQDs/Cu2O acts on five types of cancer cells, namely HeLa, A549, HT-29, SKOV3 and BABL-3T3, for 72h, the IC50 value is 1.25-18.9[mu]g.mL<-1>, the cancer cell proliferation inhibiting effect is higher than the normal cell proliferation inhibiting effect, and the toxicity and side effects on normal cells are relatively low; when the concentration is 12.5[mu]g.mL<-1>, the cancer cell inhibiting rate is higher than 50%; the CQDs/Cu2O has the strongest SKOV3 cell inhibiting effect, and the IC50 value is 12.5[mu]g.mL<-1>; the CQDs/Cu2O is the most sensitive toSKOV3 cells.

The invention discloses application of Cephaloziellin B in the preparation of a medicine for treating an ovarian cancer, and belongs to the field of medicines. A research shows that the Cephaloziellin B has an inhibition effect on the proliferation of SKOV3 cells of the ovarian cancer, the inhibition rate is concentration-dependent and time-dependent, and the Cephaloziellin B can be further researched and developed to prepare the medicine for treating the ovarian cancer.

The invention provides a herba balanophorae involucratae extract. The extract is an extract of an alcohol-soluble substance position obtained after herba balanophorae involucratae is subjected to water extraction and then is subjected to alcohol precipitation treatment or an extract of an ethyl-acetate position obtained after a supernatant solution, which is obtained after the herba balanophorae involucratae is subjected to the water extraction and then is subjected to the alcohol precipitation treatment, is abstracted through ethyl acetate or an extract of a water-extracted and alcohol-precipitated position obtained after a precipitate, which is obtained after the herba balanophorae involucratae is subjected to the water extraction and then is subjected to the alcohol precipitation treatment, is washed through alcohol and dried. According to the herba-balanophorae-involucratae extract, the herba-balanophorae-involucratae extract is applied to the preparation of a medicine for treatingan ovarian cancer and shown by an experiment, the herba-balanophorae-involucratae extract can be used for inhibiting the growth of A2780 and SKOV3 cells for the ovarian cancer in vitro in a dose-dependent manner, can be used for obviously inhibiting the growth of an A2780 nude-mice transplantation tumor in vivo and has a better effect.

The invention discloses an application of Chenopodolin in preparation of medicines for treating an ovarian cancer, and belongs to the field of medicines. An in vitro test proves that the Chenopodolin is capable of inhibiting proliferation activity of an ovarian cancer SKOV3 cell; an MTT result shows that distribution of a cell cycle is affected by the Chenopodolin; tumor cells are retarded at a G0/G1 stage; meanwhile, the Chenopodolin can be combined with a tyrosine kinase phosphorylation ATP binding site of an EGFR/HER2 acceptor to inhibit phosphorylation of tyrosine kinase, so that cell apoptosis is induced by down-regulating expression of HER2 and P-HER2 protein; and the Chenopodolin can be further researched and developed into the medicines for treating the ovarian cancer.

MEHP treatment significantly increases the migration and invasion ability of tumor cells, and the results show that MEHP can induce epithelial-mesenchymal transition of ovarian cancer cells. SKOV3 cells treated by the MEHP with a concentration of 500nM are subjected to transcription group sequencing by a high-throughput sequencing method, the sequencing result is analyzed, and 39 confirmed long-chain non-coding RNAs are screened out; and in the differentially-expressed 39 lnc RNAs, the results show that linc00205 plays an important role in the ovarian cancer cell migration, invasion ability improvement and epithelial-mesenchymal transition induced by the MEHP.

The invention discloses an application of ledene in a cervical cancer treatment aspect. It is discovered that gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have the excellent anti-proliferative effect to a human ovarian cancer SKOV3 cell and a human cervical cancer Hela cell; and although the ledene is a dehydration product of palustrol from a chemical structure, and the chemical structure is more similar, a difference of proliferation inhibition activity to the human ovarian cancer SKOV3 cell and the human cervical cancer Hela cell is larger, wherein the ledene is apparent for the anti-proliferative effect to the human cervical cancer Hela cell, and not apparent for the anti-proliferative effect to the human ovarian cancer SKOV3 cell, but the palustrolis apparent for the anti-proliferative effect to the human ovarian cancer SKOV3 cell, and not apparent for the anti-proliferative effect to the human cervical cancer Hela cell. All of the ledene, thepalustrol, the gweicurculactone, the isorupestonic acid, the 7-aromadendrene-6-ketone and the 4-aromadendrene can be used for treating gynecological oncology.

The invention discloses use of ledol in treating ovarian cancer. The present inventors have found that cinnabarinol, isoamyl sulphonic acid, 7-seriesene ketone, and ketone orange have excellent proliferation inhibition effects on human ovarian cancer SKOV3 cells and human cervical cancer Hela cells; Although the chemical structure is a dehydration product of tallow tea alcohol, the chemical structure is similar, but the proliferation inhibitory activity of human ovarian cancer SKOV3 cells and human cervical cancer Hela cells is quite different, among which: trumpet tea is on the cervical cervix. The proliferation inhibition effect of cancer Hela cells was obvious, and the inhibition of proliferation of human ovarian cancer SKOV3 cells was not obvious, while tallow tea alcohol inhibited theproliferation of human ovarian cancer SKOV3 cells, and inhibited the proliferation of human cervical cancer Hela cells. Terpene catechin, trumpet tea alcohol, cinnabarinol, isoamyl sulphonic acid, 7-mannitol ketone and 4 citron are all used for the treatment of gynecological tumors.

The invention provides application of timosaponin I in preparation of anti-human ovarian cancer drugs, and belongs to the technical field of new medical application of the timosaponin I. The molecular formula of the timosaponin I is C39H66O14, and the chemical structural formula of the timosaponin I is shown in the specification. The timosaponin I can effectively inhibit expression of mRNA of SHH signal channel related target genes and protein GLI1 and SUFU in human ovarian cancer cells SKOV3; the timosaponin I can effectively inhibit proliferation, epithelial-mesenchymal transition (EMT), migration and invasion of SKOV3 cells, and it is indicated that the timosaponin I is expected to be developed into an effective component of the medicine for resisting the human ovarian cancer. In addition, the medicine can be prepared into different preparation forms according to the requirements of patients, is convenient for the patients to take, and has better development and application prospects.

The invention discloses a medical application of isorupestonic acid for treating gynecological tumors. The medical application discovers that Gui curcumalactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have excellent proliferation-inhibiting effect for human ovarian cancer SKOV3 cells and human cervical cancer Hela cells; ledene is a dewatered product of ledol from chemical structure, the chemical structures are more similar, but the difference of the human ovarian cancer SKOV3 cells and the human cervical cancer Hela cells is larger in proliferation-inhibiting activity, wherein the ledene has obvious proliferation-inhibiting effect for the human cervical cancer Hela cells, and has no obvious proliferation-inhibiting effect for the human ovarian cancer SKOV3 cells,but the ledol has obvious proliferation-inhibiting effect for the human ovarian cancer SKOV3 cells, and has no obvious proliferation-inhibiting effect for the human cervical cancer Hela cells. All the ledene, the ledol, the Gui curcumalactone, the isorupestonic acid, the 7-aromadendrene-6-ketone and the 4-aromadendrene can be used for treating the gynecological tumors.

The invention discloses medical application of 7-aromadendrene-6-ketone or 4-aromadendrene in the field of gynaecology. The invention discovers that gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have an excellent proliferation inhibition effect on human ovarian cancer SKOV3 cells and human cervical cancer Hela cells; despite that ledene is a dehydrated productof ledol in chemical structure, and has a relatively similar chemical structure, ledene shows great difference in the proliferation inhibition activity on the human ovarian cancer SKOV3 cells and human cervical cancer Hela cells, wherein the ledene realizes an obvious proliferation inhibition effect on the human cervical cancer Hela cells but an unapparent proliferation inhibition effect on the human ovarian cancer SKOV3 cells, while the ledol realizes an obvious proliferation inhibition effect on the human ovarian cancer SKOV3 cells but an unapparent proliferation inhibition effect on the human cervical cancer Hela cells. The ledene, the ledol, the gweicurculactone, the isorupestonic acid, the 7-aromadendrene-6-ketone and the 4-aromadendrene all can be used for treating gynecological tumors.

The invention discloses a paclitaxel and platinum co-loaded targeting long-circulating liposome and application thereof. The liposome is formed by reacting paclitaxel, platinum drugs, a DSPE-G2000-ES targeting fragment, an mPEG2000-DSPE long-acting fragment, lecithin and cholesterol; wherein the platinum medicine is prepared from any one of cis-platinum, oxaliplatin and carboplatin. According to the paclitaxel platinum co-loaded targeting long-circulating liposome, a targeting fragment is used as a fragment for specifically recognizing an estrogen receptor, specifically recognizes and is combined with the estrogen receptor on the surface of an SKOV3 cell, so that the ingestion of the liposome is increased; the long-acting fragment reduces the capture interference of the liposome with albumin and reticuloendothelial systems in vivo, and prolongs the circulation time of the liposome in vivo; the IC50 value of the liposome to SKOV3 cells is 0.20-0.23 [mu]M, the tumor inhibition rate is 65-90%, and the liposome has a very good anti-ovarian cancer effect.

The invention belongs to the technical field of medicines, and particularly relates to a benzylamino-substituted fatty acid derivative as well as a preparation method and application thereof. The benzylamino-substituted fatty acid derivative disclosed by the invention is (R, E) 5-(benzyloxy)-2-hexylhexadecane-2-olefine acid, and is obtained by synthesizing a raw material 3-hexyltetrahydro-4-hydroxy-6-undecyl-2H-pyran-2-ketone, and the raw material has the following structural formula shown in the description. Under the test concentration of 40 [mu] M, the inhibition rate of the prepared derivative on pancreatic cancer PANC-1, head and neck cancer TCA8113 and breast cancer MCF-7 cells is up to 80% or above, the inhibition rate on liver cancer HepG2, nasopharynx cancer CNE-2, kidney cancer A498 and bladder cancer T24 cells is 70-80%, the inhibition activity on ovarian cancer SKOV3 cells can reach 65.8%, and the derivative can be applied to preparation of antitumor drugs.

The invention discloses a compound with chemotherapy and phototherapy anti-tumor effects. The chemical name of the compound is monochloro-chloro-(9-anthracene-N4-methylthiosemicarbazide)-pentamethylcyclopentadienyl rhodium (III), and the structural formula of the compound is shown in the description. The compound has good inhibitory effects on human prostate cancer PC3 cells, human ovarian cancerSKOV3 cells, and high blood pressure, and can be used for preparing drugs for treating prostate cancer, ovarian cancer and hypertension.

The invention discloses a compound with an anti-tumor effect. The chemical name of the compound is monochloride-chlorine-(9-anthracene-N<4>-phenyl thiosemicarbazide)-pentamethyl cyclopentadienyl rhodium (III); the structure formula of the compound is shown in description. The compound has a very good inhibition effect on human prostate cancer PC3 cells and human ovarian cancer SKOV3 cells, and canbe used for preparing medicine for treating prostate cancer and ovarian cancer.

The invention discloses application of gweicurculactone in the aspect of treating gynecological tumor. The application finds gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have excellent proliferation inhibiting effect on human ovarian cancer SKOV3 cell and human cervical cancer Hela cell; although camelliene is a dehydration product of ledol in chemical structure which is similar, camelliene is different from ledol in activity of inhibiting proliferation of the human ovarian cancer SKOV3 cell and the human cervical cancer Hela cell, wherein camelliene has obvious inhibiting effect on human cervical cancer Hela cell proliferation and unobvious inhibiting effect on human ovarian cancer SKOV3 cell proliferation, but ledol has obvious inhibiting effect on human ovarian cancer SKOV3 cell proliferation and unobvious inhibiting effect on human cervical cancer Hela cell proliferation. Camelliene, ledol, gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene can all be used for treating the gynecological tumor.